Keymed Biosciences reports H1 2026 revenue of 617 million RMB driven by core product Kangyueda
Executive summary: Keymed Biosciences published interim financial results for H1 2026, reporting total revenue of 617 million RMB and Kangyueda product revenue of 393 million RMB. The figures provide investors with a concrete measure of the company’s commercial progress in its core therapeutic area and signal momentum for future growth.
Who is involved: Keymed Biosciences (HKEX:02162), its management team, and the Hong Kong Exchange as the listing venue.
Likely next: The company will file the full interim report with HKEX and may host an earnings call to discuss the results in the coming weeks.
On 19 August 2026 Keymed Biosciences (HKEX:02162) released its interim results for the six months ended 30 June 2026, showing total revenue of 617 million RMB. The company’s flagship product, Kangyueda, contributed 393 million RMB of that total. The results were announced simultaneously in Spanish, German and French press releases, confirming the figures across markets. No profit or guidance figures were disclosed in the releases.
Timeline
- — Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales (PR Newswire)
- — Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt (PR Newswire)
- — Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités (PR Newswire)
Analysis — what this means
Sectors affected
- Biotechnology
- Pharmaceuticals
- Healthcare
Key entities
Sources
- Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales — PR Newswire
- Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt — PR Newswire
- Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités — PR Newswire
Related cases
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by its Kangyueda product
- Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by flagship Kangyueda sales
- Keymed Biosciences posts strong H1 2026 growth, with core product Kangyueda sales up 132% YoY, underscoring momentum in China's biotech sector